天津医药
天津醫藥
천진의약
TIANJIN MEDICAL JOURNAL
2014年
12期
1189-1192,1250
,共5页
刘应莉%张秋瓒%王艳荣%杨倩%付丽娜%张静
劉應莉%張鞦瓚%王豔榮%楊倩%付麗娜%張靜
류응리%장추찬%왕염영%양천%부려나%장정
氧化性应激%大鼠,Sprague-Dawley%替米沙坦%多烯磷脂酰胆碱%非酒精性脂肪性肝炎%胰岛素抵抗
氧化性應激%大鼠,Sprague-Dawley%替米沙坦%多烯燐脂酰膽堿%非酒精性脂肪性肝炎%胰島素牴抗
양화성응격%대서,Sprague-Dawley%체미사탄%다희린지선담감%비주정성지방성간염%이도소저항
oxidative stress%rats,Sprague-Dawley%telmisartan%polyene phosphatidylcholine%nonalcoholic steato-hepatitis%insulin resistance
目的:探讨替米沙坦对非酒精性脂肪性肝炎(NASH)大鼠血脂及氧化应激及胰岛素抵抗的影响。方法采用随机数字表法将50只雄性SD大鼠随机分为对照组、模型组、多烯磷脂酰胆碱组、替米沙坦低剂量组和替米沙坦高剂量组,每组10只。对照组以普通饲料喂养,模型组和干预组给予高脂饲料喂养诱发NASH,12周后,分别给予生理盐水1.0 mL/(kg·d)、生理盐水1.0 mL/(kg·d)、多烯磷脂胆碱8.4 mg/(kg·d)、替米沙坦4 mg/(kg·d)和替米沙坦8 mg/(kg·d)灌胃4周。所有大鼠在第16周末处死,测肝酶、血脂、氧化应激、胰岛素抵抗指数(HOMA-IR)等及肝组织NAS评分。结果与模型组比较,多烯磷脂酰胆碱组丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)减低,NAS评分改善;替米沙坦低剂量组AST减低,血清总抗氧化能力(T-AOC)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)、肝组织SOD和GSH-PX提高,血清及肝组织MDA减低,HOMA-IR减低,NAS评分改善;替米沙坦高剂量组ALT减低,余指标变化同替米沙坦低剂量组。结论高剂量的替米沙坦可降低NASH大鼠肝酶、氧化应激、胰岛素抵抗和肝脏脂质沉积,且作用优于多烯磷脂酰胆碱及低剂量替米沙坦。
目的:探討替米沙坦對非酒精性脂肪性肝炎(NASH)大鼠血脂及氧化應激及胰島素牴抗的影響。方法採用隨機數字錶法將50隻雄性SD大鼠隨機分為對照組、模型組、多烯燐脂酰膽堿組、替米沙坦低劑量組和替米沙坦高劑量組,每組10隻。對照組以普通飼料餵養,模型組和榦預組給予高脂飼料餵養誘髮NASH,12週後,分彆給予生理鹽水1.0 mL/(kg·d)、生理鹽水1.0 mL/(kg·d)、多烯燐脂膽堿8.4 mg/(kg·d)、替米沙坦4 mg/(kg·d)和替米沙坦8 mg/(kg·d)灌胃4週。所有大鼠在第16週末處死,測肝酶、血脂、氧化應激、胰島素牴抗指數(HOMA-IR)等及肝組織NAS評分。結果與模型組比較,多烯燐脂酰膽堿組丙氨痠轉氨酶(ALT)、天鼕氨痠轉氨酶(AST)減低,NAS評分改善;替米沙坦低劑量組AST減低,血清總抗氧化能力(T-AOC)、超氧化物歧化酶(SOD)、穀胱甘肽過氧化物酶(GSH-PX)、肝組織SOD和GSH-PX提高,血清及肝組織MDA減低,HOMA-IR減低,NAS評分改善;替米沙坦高劑量組ALT減低,餘指標變化同替米沙坦低劑量組。結論高劑量的替米沙坦可降低NASH大鼠肝酶、氧化應激、胰島素牴抗和肝髒脂質沉積,且作用優于多烯燐脂酰膽堿及低劑量替米沙坦。
목적:탐토체미사탄대비주정성지방성간염(NASH)대서혈지급양화응격급이도소저항적영향。방법채용수궤수자표법장50지웅성SD대서수궤분위대조조、모형조、다희린지선담감조、체미사탄저제량조화체미사탄고제량조,매조10지。대조조이보통사료위양,모형조화간예조급여고지사료위양유발NASH,12주후,분별급여생리염수1.0 mL/(kg·d)、생리염수1.0 mL/(kg·d)、다희린지담감8.4 mg/(kg·d)、체미사탄4 mg/(kg·d)화체미사탄8 mg/(kg·d)관위4주。소유대서재제16주말처사,측간매、혈지、양화응격、이도소저항지수(HOMA-IR)등급간조직NAS평분。결과여모형조비교,다희린지선담감조병안산전안매(ALT)、천동안산전안매(AST)감저,NAS평분개선;체미사탄저제량조AST감저,혈청총항양화능력(T-AOC)、초양화물기화매(SOD)、곡광감태과양화물매(GSH-PX)、간조직SOD화GSH-PX제고,혈청급간조직MDA감저,HOMA-IR감저,NAS평분개선;체미사탄고제량조ALT감저,여지표변화동체미사탄저제량조。결론고제량적체미사탄가강저NASH대서간매、양화응격、이도소저항화간장지질침적,차작용우우다희린지선담감급저제량체미사탄。
Objective To investigate the effects of telmisartan on insulin resistance and oxidative stress in nonalco?holic steatohepatitis (NASH) rats. Methods Fifty male SD rats were randomly divided into five groups:control group, mod?el group, polyene phosphatidylcholine group, low-dose telmisartan group and high-dose telmisartan group by using random number table (n=10 in each group). Control group was given standard food,the other groups were given high fat diet for 12 weeks to establish NASH rat model. Then intervention groups were given either normal saline 1.0 mL/(kg·d) or polyene phos?phatidylcholine 8.4 mg/(kg·d), or telmisartan 4 mg/(kg·d) or telmisartan 8 mg/(kg·d) for 4 weeks by intragastric adminstra?tion. All rats were sacrificed at the end of the 16th week, the lever of plasma insulin resistance index (HOMA-IR), ALT, AST, TG, TC, MDA, SOD, T-AOC, CAT, GSH-PX and liver homogenate MDA, SOD, GSH-PX and liver NAS scores were tested. Results In polyene phosphatidylcholine treated group, the lever of plasma ALT, AST, HOMA-IR and liver NAS scores were degreased significantly compared with model group. The lever of plasma AST, SOD, T-AOC, CAT, GSH-PX and liver homogenate SOD, GSH-PX, liver NAS scores were improved in both low-dose and high-dose telmisartan groups com?pared with model group while plasma and liver homogenate MDA , HOMA-IR were reduced significantly in these two groups compared with model group. Besides, plasma ALT was significantly improved in high-dose telmisartan group compared with model group. Conclusion Telmisartan reduce plasma ALT, AST, oxidative stress, HOMA-IR and liver NAS scores in NASH rats. And high-does telmisartan is better than low-dose telmisartan and polyene phosphatidylcholine in treatment ef?fect.